Colorectal cancer peritoneal metastasis
Conditions
Interventions
Cisplatin+Docetaxel Group:Preoperative intravenous injection of 5-FU (400 mg/m2) by a doctor or nurse, followed by CRS+HIPEC treatment. After completing CRS, the patient underwent HIPEC treatment with
Mitomycin group:Preoperative intravenous injection of 5-FU (400 mg/m2) by a doctor or nurse, followed by CRS+HIPEC treatment. After completing CRS, the patient received HIPEC treatment with mitomycin
Sponsors
Tsinghua Changgung Hospital, Beijing
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged >= 18 and = 60 points, expected survival period greater than 12 months; 4. No severe hematological, liver or kidney dysfunction, and important organ function can tolerate CRS+HIPEC treatment; 5. No history of allergies to fluorouracil, mitomycin C, docetaxel, or cisplatin; 6. The patient or their authorized representative understands and cooperates with the treatment and voluntarily signs a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known to have alcohol and/or drug dependence; 2. Individuals with mental or psychological disorders who are unable to cooperate with treatment and efficacy evaluation; 3. Simultaneously suffering from other incurable malignant tumors; 4. Patients with infectious diseases (such as HBV, HCV, HIV antibody positive, RPR positive, active tuberculosis, etc.), or other serious infections (viruses, bacteria, fungi) that require systemic treatment; 5. Coagulation disorders (such as hemophilia); 6. Pregnant or lactating women, or women with pregnancy plans within six months; 7. Patients who are currently taking immunosuppressive drugs or long-term use of anti rejection drugs after organ transplantation; 8. Patients with severe autoimmune diseases; 9. Participate in other clinical studies within 3 months prior to the start of this study. 10. According to the researchers' judgment, patients who are not suitable to participate in this study due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome labeled with 5-FU in tumor specimens;Transcriptome labeled with 5-FU in blood samples; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of serious adverse events;Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactGang Liu
Beijing Tsinghua Changgung Hospital (School of Clinical Medicine, Tsinghua University)
Outcome results
None listed